Advertisement

Molecular Insight Pharmaceuticals, Inc. has filed for chapter 11 bankruptcy protection, in a deal that will secure the company a $45 million cash infusion from a private investment company.

The Cambridge-based CEO Daniel Peters has resigned, as has Charles Abdalian, the chief financial officer, as part of the deal with San Francisco-based Savitr Capital LLC.

SOURCE

Advertisement
Advertisement